| 2026-08-12 | Press release | Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Impr |
| 2026-08-07 | Press release | Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Recept |
| 2026-07-30 | Earnings deck | Earnings deck |
| 2026-07-30 | Press release | Latest News Releases Read More |
| 2026-07-23 | Press release | Neurocrine Biosciences Announces Key Leadership Hiring, Promotions |
| 2026-07-21 | Press release | Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer |
| 2026-07-01 | Press release | Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Cong |
| 2026-06-15 | Press release | Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Im |
| 2026-06-15 | Press release | Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in P |
| 2026-06-15 | Press release | Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabol |
| 2026-06-15 | Press release | Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic C |
| 2026-06-08 | Press release | Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valben |
| 2026-06-08 | Press release | Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing |
| 2026-06-03 | Press release | Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outc |
| 2026-05-26 | Press release | Neurocrine Biosciences to Present at Upcoming Investor Conferences in June |
| 2026-05-18 | Press release | Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and I |
| 2026-05-18 | Press release | Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics |
| 2026-05-06 | Press release | Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiatin |
| 2026-05-05 | Press release | Neurocrine Biosciences Reports First-Quarter 2026 Financial Results |
| 2026-05-05 | Press release | Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 |
| 2026-05-05 | Earnings deck | Download |
| 2026-05-04 | Press release | Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment |
| 2026-05-04 | Press release | Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing F |
| 2026-05-01 | Press release | Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Redu |
| 2026-04-29 | Press release | Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dy |
| 2026-04-22 | Press release | Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reduc |
| 2026-04-14 | Press release | Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistenc |
| 2026-04-06 | Press release | Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio |
| 2026-03-26 | Press release | Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings |
| 2026-03-17 | Press release | Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer |
| 2026-03-10 | Press release | Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum |
| 2026-02-24 | Press release | Neurocrine Biosciences to Present at Upcoming Investor Conferences in March |
| 2026-02-11 | Press release | Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations f |
| 2026-01-26 | Press release | Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia |
| 2026-01-21 | Press release | Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results |
| 2026-01-15 | Press release | Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occ |
| 2026-01-05 | Press release | Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-06-30 | ESG report | Neurocrine Biosciences 2025 Corporate Responsibility Report |
| 2024-10-30 | Press release | Press Release |
| 2024-04-06 | Annual report | 2023 Annual Report* |